Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05090605
Other study ID # 1186
Secondary ID
Status Completed
Phase
First received
Last updated
Start date March 30, 2022
Est. completion date January 20, 2023

Study information

Verified date March 2023
Source Asfendiyarov Kazakh National Medical University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a GWAS study that aims to identify possible candidate genes associate to breast cancer by exploring single nucleotide polymorphism (SNP) in a group of breast cancer, in the Kazakh population. The investigators hypothesize that the careful phenotyping of the subject sand matching with increase the power to find SNP significantly associate with breast cancer


Description:

A genome-wide association study (GWAS) is an approach used in genetics research to associate specific genetic variations with particular diseases. The method involves scanning the genomes from many different people and looking for genetic markers that can be used to predict the presence of a disease. Once such genetic markers are identified, they can be used to understand how genes contribute to the disease and develop better prevention and treatment strategies.


Recruitment information / eligibility

Status Completed
Enrollment 700
Est. completion date January 20, 2023
Est. primary completion date January 20, 2023
Accepts healthy volunteers
Gender Female
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: - Persons with a histologically confirmed diagnosis of breast cancer. - The age of patients is from 18 to 60 years; - Persons of Kazakh nationality, whose paternal and maternal grandparents are Kazakhs. - Persons who are able and willing to provide written informed consent; - Persons capable and willing to comply with the research protocol; Exclusion Criteria: - Persons under 18 and over 60 years old; - Persons who, in the opinion of the researcher, are mentally or legally incapacitated, which prevents obtaining informed consent; - Pregnant or lactating women; - Tuberculosis of any localization in the active phase and in history; - Severe and decompensated diseases of the liver and kidneys, cardiovascular system; - Severe and decompensated course of endocrine diseases; - Lack of histological verification of breast tumor

Study Design


Related Conditions & MeSH terms


Intervention

Genetic:
DNA analysis
GWAS

Locations

Country Name City State
Kazakhstan JSC "Kazakh Institute of Oncology and Radiology" Almaty
Kazakhstan JSC "Kazakh Institute of Oncology and Radiology", Almaty, Kazakhstan Almaty

Sponsors (1)

Lead Sponsor Collaborator
Asfendiyarov Kazakh National Medical University

Country where clinical trial is conducted

Kazakhstan, 

Outcome

Type Measure Description Time frame Safety issue
Primary number of SNPs associated with breast cancer Using GWAS to identify candidate genes associate with breast cancer 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2